Abstract
Coronary drug-eluting stent (DES) development has included new metal alloys, changes in stent architecture and bioresorbable polymers. Emerging evidence from comparative study demonstrates improved safety and efficacy with ultrathin-strut DES. BIOFLOW V (ClinicalTrials.gov [NCT02389946][1]) was an
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
